EC approves Watson's pending acquisition of Actavis

Download PDF Copy

Oct 6 2012

NewsGuard 100/100 Score

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the European Commission (EC) has approved the company's pending acquisition of the privately held Actavis Group.

"Approval from the EC represents a significant milestone as we work toward the completion of the combination of Watson and Actavis later this year," said Paul Bisaro, Watson's President and CEO.

The transaction remains subject to regulatory approval in the United States from the Federal Trade Commission (FTC). Watson continues to expect the transaction to close in the fourth quarter of 2012.

Source:

Watson Pharmaceuticals, Inc.

Posted in: Business / Finance

Tags: Oncology, Pharmaceuticals, Urology

Comments (0)

Download PDF Copy

Suggested Reading

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Rising asthma rates in sub-Saharan Africa linked to urbanization and lack of care

Rising asthma rates in sub-Saharan Africa linked to urbanization and lack of care

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Antibiotic resistance threatens millions of lives worldwide